![]() |
Can oral insulin succeed where other alternative delivery methods have failed? Dan Stanton, from in-Pharmatechnologist.com assesses its chances. Related news |
Pfizer and other EU industry and academic groups are calling on the European Commission to revise its plans for authorizing and regulating ATMPs (advanced therapy medical products).
Sandoz has recalled two lots of an injectable drug after vials were discovered to contain foreign matter, though is unsure of the cause for now.
Disposable bioreactors could be the centerpiece of a project to develop and harvest large quantities of cells that eventually will be used in bioartificial livers for patients with severe liver failure.
Faced with manufacturing quality questions that caused the FDA to reject its potential Parkinson’s disease treatment, Impax Laboratories has hired a committee of specialists to oversee quality improvements at its California facility.
As CROs and pharmaceutical sponsors must begin collecting data in August to comply with the Sunshine Act, some companies are now looking to service providers for help.
The Association of Clinical Research Organizations (ACRO) has joined a small business coalition as part of its effort to halt the decline of capital into biomedical research.
Three Canadian drug companies have issued a voluntary recall following potential contamination during manufacturing of an API by their Chinese CMO.
GlaxoSmithKline (GSK) says some manufacturing from the shuttering of an Australian packaging site will be picked up by Aspen and local third-party contractors.
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Patheon, Hospira and SCM Pharma.